Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05065762 · ClinicalTrials.gov registry record

Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment

A clinical trial of Psoriasis, sponsored by Bristol-Myers Squibb.

Completed
Registry status
232
Enrollment target
1
Study location

NCT05065762: Completed study of Psoriasis, sponsored by Bristol-Myers Squibb.

NCT05065762 is a study of Psoriasis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 232 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05065762, a study of Psoriasis, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
232 participants
Enrollment target
1
Study location

Study Summary

The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.

Conditions Studied

Study Locations (1)

North Carolina

  • Local Institution - Morrisville

Trial Details

FieldValue
Enrollment Target 232 participants
Start Date 2021-10-01
Est. Completion 2022-02-07
Bristol-Myers Squibb

1,025 total trials

What the finished NCT05065762 record still lists

NCT05065762 is an observational study that tracks outcomes without assigning an intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (52% lower).

The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 0 interventions.

NCT05065762 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT05065762 about?

NCT05065762 is a clinical study titled "Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment". The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.

What is the current status of trial NCT05065762?

This trial is currently completed. The enrollment target is 232 participants. The study started on 2021-10-01. Estimated completion is 2022-02-07.

What conditions does trial NCT05065762 study?

This clinical trial studies the following conditions: Psoriasis.

Who is sponsoring clinical trial NCT05065762?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05065762 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05065762's enrollment target sits among peer trials

232 37th of 125 higher than 89 of 125 other Psoriasis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01356290 · 232 participants · Phase 2

    Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

  • NCT04753359 · 232 participants · NA

    Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer

  • NCT04770870 · 232 participants · NA

    Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System

  • NCT05948943 · 232 participants · Phase 2

    Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05065762, the US trial registry maintained by the National Library of Medicine. NCT05065762 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.